Aelius Biotech

Executive Summary

Aelius Biotech is a UK-based biotechnology company specializing in advanced in vitro gut modeling using proprietary mucus-enabled 3D gut models. Founded in 2020, the company provides physiologically relevant data on digestion and absorption for orally delivered products, targeting oncology, immunology, and broader life sciences. By enabling more predictive preclinical testing, Aelius aims to de-risk R&D and accelerate product development for pharmaceutical and biotech clients. The company's technology addresses a critical gap in oral drug development, where traditional models often fail to replicate the complex gut environment, leading to costly late-stage failures. With the growing demand for alternatives to animal testing and more human-relevant models, Aelius is well-positioned to capitalize on regulatory shifts and industry trends. The company's service-based business model offers recurring revenue potential and scalability. However, as a relatively young company with limited public information, its commercial traction and competitive landscape remain unverified. Aelius operates in a niche but expanding market, facing competition from established CROs and emerging organ-on-chip platforms. Its success hinges on securing key partnerships, demonstrating superior predictive power, and expanding its service offerings to cover additional therapeutic areas.

Upcoming Catalysts (preview)

• Q3 2026Launch of new IBD-specific gut model70% success
• Q4 2026Strategic partnership with top-20 pharma for oral drug testing50% success
• Q3 2026Publication of validation study in peer-reviewed journal80% success